DB19416InvestigationalProtein Based Therapies
Mevonlerbart is under investigation in clinical trial NCT06602726 (A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy).
- Also known as
- Anti-cat allergen fel d 1 monoclonal anitbody regn-1909 · gamma4 heavy chain Homo sapiens (1-442) [VH (Homo sapiens IGHV3-23*04 (94.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115)-Homo sapiens IGHG4*01, G4v5 h P10, nG4m(a) CH2 L92 (CH1(116-213), hinge 1-12 S10>P (223) (214-225), CH2 · Immunoglobulin G4 [223-proline], anti-(Felis catus allergen Fel d1) (human monoclonal REGN1909 γ4-chain), disulfide with human monoclonal REGN1909 κ-chain, dimer · immunoglobulin G4-kappa, anti-[Fel d 1 (Felis silvestris catus (domestic cat) allergen 1)], Homo sapiens monoclonal antibody
- Code names
- REGN-1909
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Mevonlerbart, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account